# High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL

> **NCT00828282** · PHASE1 · COMPLETED · sponsor: **John Haslip** · enrollment: 3 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT00828282
- **Lead sponsor:** John Haslip
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-01
- **Final completion:** 2014-04
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2014-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00828282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00828282, "High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00828282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*